In ‘Real Life’ this 10-day Ivermectin Triple Therapy reported here, appears to be a very safe, effective and inexpensive early antiviral treatment for Covid-19. Further detail from the more than 30 doctors involved in treating this patient group, will be used for a formal peer-reviewed publication.
ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024).
Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
The French scientists concluded, “This study supports the use of immunomodulatory drugs such as ivermectin, to improve the clinical condition of SARS-CoV-infected patients.”
Altogether, this study brings the proof of concept that an IVM-based immunomodulatory therapy improves the clinical condition of SARS-CoV-2-infected hamsters, and in clinical trials, it alleviates symptoms of COVID-19 in humans and possibly limits post-COVID-19 syndrome (also known as long COVID) via an anti-inflammatory action.
Dr. Risch gives a succinct history of the politics of hydroxychloroquine and other useful existing medicines in the USA, which has had global effect, as many countries look to the USA for guidance. Corruption and manipulation from behind the scenes around the world are brought to the surface for scrutiny.
Source: Rounding The Earth Author: Mathew Crawford Fifty years ago today, the New York Times began publication of the Pentagon Papers, informing the public about how a government-engineered
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.
We discussed the Surgisphere debacle and other stories of “engineered research” during the pandemic, most of which I am currently preparing articles about.
Ivermectin had a significant effect (p=0.003) in achieving medical release. The treatment with ivermectin could significantly prevent the evolution to serious stages since the experimental group did not present any patient with referral to critical hospitalization.
The Hydroxychloroquine Hypothesis: That there is some appropriate dosage of hydroxychloroquine, alone or in some combination with other medication, that successfully prevents some COVID-19 cases (PrEP/PEP) or treats some COVID-19 sufferers (Early/Late/Critical).
Remaining entirely unblemished after a year of trials and observations, the current evidence in favor of the Primary HCQ Hypothesis fully validates the HCQ Hypothesis. The logic is so simple that it almost feels like your livelihood would have to be on the line to deny it.
This is now one of the most well-studied treatments in the history of medicine, and the evidence is overwhelming. The chance that these results could occur at random is approximately 1 in 208 quadrillion. That is, p = 0.000000000000048. Having read a few thousand research papers, I have never before seen a p-value this low in the testing of medicine.
Why then does the pharmaceutical industry and its promoters insist on conducting RCTs before something is accepted as true? RCTs take substantial amounts of time and significant resources to conduct. This creates a barrier to entry, especially for inexpensive solutions to medical problems. In other words, the myth that RCTs are some necessary “gold standard” is a deception that, along with regulatory agency, prevent any possibility for simpler and less expensive (less profitable) medical solutions to gain traction.
If the argument rests on “RCTs as the gold standard”, there is little doubt that the evidence dramatically favors using HCQ as a standard early stage therapeutic! But it is reasonable to assess the quality of all the evidence to reach beyond gold for the ultimate and supreme standards of scientific evidence. That too we plan to present in future articles.
In this study of COVID-19, for infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization
HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).
No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.
Results obtained in the prophylaxis of Q fever indicate that chloroquine/hydroxychloroquine can be successfully used in the clinical management of infections other than malaria.
Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.
Figure 3 reported random forest for 10 studies comparing HCQ+AZM. Use of the combination HCQ+AZM was associated with 25% lower mortality risk
WMA DECLARATION OF HELSINKI – ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS
This means that zinc, low dose HCQ, and azithromycin and may prevent a large number of hospitalizations and probably deaths during the SARS-CoV-2 pandemic.
We found a higher survival rate in patients treated with hydroxychloroquine and with macrolides in our study.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 115 studies to date is estimated to be 1 in 20 million (p = 0.000000049).
This study of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Mexico demonstrated that age and CRP levels upon ICU admission were associated with in-hospital mortality
Our results can assure that hydroxychloroquine used for COVID-19 patients is safe, highly tolerable, and with minimum side effects.
The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients.
HCQ has greater efficacy if given earlier in the course of the disease. Several negative studies have been withdrawn due to methodological improprieties.
Hydroxychloroquine had a modest effect on hospital length stay and days in ICU compared with Standard Care.
Our findings indicate that Hydroxychloroquine can be an effective agent in postexposure prophylaxis.
Source: C19Study A live and ongoing index of studies from around the world documenting the use of hydroxychloroquine in treatment at various stages of SARS-CoV-2 infection
Hydroxychloroquine seems to be safe, regardless of the clinical setting in which it is started, so long as an adequate ECG monitoring strategy is in place.
Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.
These results are evidences to support the early use of HCQ in post exposure prophylaxis.
To have covered up the knowledge for four decades that viruses could potentially be treated by antimicrobials required extensive effort
In this trial, no deaths occurred related to hydroxychloroquine, and serious side effects were rare.
An Urgent Call to Depoliticize Medicine in the COVID-19 Pandemic
HCQ or CQ should be used efficiently alone or in combination with AZ to optimize the management of asymptomatic and mild cases of COVID-19.
‘’Treatment with an oral combination of hydroxychloroquine, azithromycin and zinc may REPRESENT THE BEST CURRENT THERAPEUTIC OPTION in relation to its antiviral and immunomodulatory effects’’.
It could be possible that this treatment only works when used early and in particular patient groups with similar characteristics as in the present study.
